Schuschel K, Helwig M, Huttelmaier S, Heckl D, Klusmann J, Hoell J
Int J Mol Sci. 2020; 21(10).
PMID: 32408494
PMC: 7279408.
DOI: 10.3390/ijms21103409.
Akahori Y, Wang L, Yoneyama M, Seo N, Okumura S, Miyahara Y
Blood. 2018; 132(11):1134-1145.
PMID: 30045840
PMC: 6148344.
DOI: 10.1182/blood-2017-08-802926.
Karim M, Tha K, Othman I, Uddin M, Chowdhury E
Pharmaceutics. 2018; 10(2).
PMID: 29861465
PMC: 6026921.
DOI: 10.3390/pharmaceutics10020065.
Rasa D, DAmico A, Maugeri G, Cavallaro S, DAgata V
J Mol Neurosci. 2017; 62(2):131-141.
PMID: 28534317
DOI: 10.1007/s12031-017-0930-0.
Maugeri G, DAmico A, Rasa D, Reitano R, Saccone S, Federico C
Genes Cancer. 2016; 7(1-2):47-58.
PMID: 27014421
PMC: 4773705.
DOI: 10.18632/genesandcancer.94.
Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies.
Di Stasi A, Jimenez A, Minagawa K, Al-Obaidi M, Rezvani K
Front Immunol. 2015; 6:36.
PMID: 25699052
PMC: 4316779.
DOI: 10.3389/fimmu.2015.00036.
Dysregulation of gene expression in the artificial human trisomy cells of chromosome 8 associated with transformed cell phenotypes.
Nawata H, Kashino G, Tano K, Daino K, Shimada Y, Kugoh H
PLoS One. 2011; 6(9):e25319.
PMID: 21980425
PMC: 3183047.
DOI: 10.1371/journal.pone.0025319.
Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response.
Takahara A, Koido S, Ito M, Nagasaki E, Sagawa Y, Iwamoto T
Cancer Immunol Immunother. 2011; 60(9):1289-97.
PMID: 21607557
PMC: 11029139.
DOI: 10.1007/s00262-011-1033-3.
An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1.
Kim M, McGarry T, Broin P, Flatow J, Golden A, Licht J
Proc Natl Acad Sci U S A. 2009; 106(27):11154-9.
PMID: 19549856
PMC: 2708714.
DOI: 10.1073/pnas.0901591106.
In silico regulatory analysis for exploring human disease progression.
Holloway D, Kon M, DeLisi C
Biol Direct. 2008; 3:24.
PMID: 18564415
PMC: 2464594.
DOI: 10.1186/1745-6150-3-24.
The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells.
Han Y, San-Marina S, Yang L, Khoury H, Minden M
Breast Cancer Res. 2007; 9(4):R43.
PMID: 17634147
PMC: 2206716.
DOI: 10.1186/bcr1743.
WT1 mutations in nephrotic syndrome revisited. High prevalence in young girls, associations and renal phenotypes.
Aucella F, Bisceglia L, De Bonis P, Gigante M, Caridi G, Barbano G
Pediatr Nephrol. 2006; 21(10):1393-8.
PMID: 16909243
DOI: 10.1007/s00467-006-0225-0.
Ikaros induces quiescence and T-cell differentiation in a leukemia cell line.
Kathrein K, Lorenz R, Innes A, Griffiths E, Winandy S
Mol Cell Biol. 2005; 25(5):1645-54.
PMID: 15713624
PMC: 549358.
DOI: 10.1128/MCB.25.5.1645-1654.2005.
FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells.
Sturla L, Merrick A, Burchill S
Br J Cancer. 2003; 89(7):1276-84.
PMID: 14520460
PMC: 2394287.
DOI: 10.1038/sj.bjc.6601249.
Identification of a DNA-binding site and transcriptional target for the EWS-WT1(+KTS) oncoprotein.
Reynolds P, Smolen G, Palmer R, Sgroi D, Yajnik V, Gerald W
Genes Dev. 2003; 17(17):2094-107.
PMID: 12923058
PMC: 196452.
DOI: 10.1101/gad.1110703.
Identification of an alternatively spliced RNA for the Ras suppressor RSU-1 in human gliomas.
Chunduru S, Kawami H, Gullick R, Monacci W, Dougherty G, Cutler M
J Neurooncol. 2003; 60(3):201-11.
PMID: 12510772
DOI: 10.1023/a:1021130620178.
Cancer immunotherapy targeting WT1 protein.
Sugiyama H
Int J Hematol. 2002; 76(2):127-32.
PMID: 12215010
DOI: 10.1007/BF02982574.
The role of WT1 in oncogenesis: tumor suppressor or oncogene?.
Loeb D, Sukumar S
Int J Hematol. 2002; 76(2):117-26.
PMID: 12215009
DOI: 10.1007/BF02982573.
The Wilms tumor suppressor WT1 regulates early gonad development by activation of Sf1.
Wilhelm D, Englert C
Genes Dev. 2002; 16(14):1839-51.
PMID: 12130543
PMC: 186395.
DOI: 10.1101/gad.220102.
Wilms' tumor gene WT1: its oncogenic function and clinical application.
Sugiyama H
Int J Hematol. 2001; 73(2):177-87.
PMID: 11372729
DOI: 10.1007/BF02981935.
